Corpus Intelligence IC Memo — LTAC OF LOUISIANA LLC 2026-04-26 14:06 UTC
IC Memo — LTAC OF LOUISIANA LLC
Investment Committee Memorandum | LA | 18 beds | Grade D | EBITDA uplift $886K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LTAC OF LOUISIANA LLC

CCN 192029 | LAFAYETTE PARISH, LA | 18 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

LTAC OF LOUISIANA LLC is a 18-bed community hospital in LAFAYETTE PARISH, LA with $12.0M in net patient revenue and a 25.2% operating margin. The hospital serves a payer mix of 70.8% Medicare, 0.0% Medicaid, and 29.2% commercial.

Thesis: Turnaround. Our ML models identify $886K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 25.2% to 32.6% (+739bps).

Net Revenue HCRIS$12.0M
Current EBITDA COMPUTED$3.0M
Operating Margin COMPUTED25.2%
Occupancy HCRIS90.2%
Revenue / Bed COMPUTED$666K
Net-to-Gross HCRIS48.6%
Distress Probability MLnan%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
106
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 25.2% places it above the state median. Among 106 size-comparable peers (9-36 beds), the median margin is -1.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (9-36), prioritizing same-state peers. 106 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LTAC OF LOUISIANA LLC (Target)LA18$12.0M25.2%
SPECIALISTS HOSPITAL OF SHREVELA15$79.1M21.3%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%
AVALALA21$64.0M7.4%
THE SPINE HOSPITAL OF LOUISIANLA23$57.4M35.4%
PARK PLACE SURGERY CENTERLA10$51.6M15.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $886K (739bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$252K+210bp18mo
Cost to Collect4.5%2.5%$240K+200bp12mo
Denial Rate Reduction12.0%6.5%$239K+199bp12mo
A/R Days Reduction5200.0%3800.0%$146K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+8bp6mo

5. EBITDA Bridge

Net Collection Rate
$252K
Cost to Collect
$240K
Denial Rate Reduction
$239K
A/R Days Reduction
$146K
Clean Claim Rate
$10K
Total EBITDA Uplift$886K
Current EBITDA$3.0M
+ RCM Uplift+$886K
Pro Forma EBITDA$3.9M
Current Margin25.2%
Pro Forma Margin32.6%
WC Released (1x)$460K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$4.7M$28.8M6.19x44.0%
Base (11x exit)10.0x11.0x$4.7M$33.2M7.14x48.1%
Bull Case9.0x11.0x$4.2M$37.6M8.99x55.1%
Bull (12x exit)9.0x12.0x$4.2M$42.3M10.10x58.8%
Bear Case11.0x10.0x$5.1M$22.9M4.47x34.9%
Bear (11x exit)11.0x11.0x$5.1M$26.8M5.24x39.3%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumHeavy Medicare dependenceMedicare comprises 70.8% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 106 hospitals with 9-36 beds
  • Same-state prioritization (n=108)
  • Comp margins: P25=-14.2% / P50=-1.8% / P75=7.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.